Answers are grounded in this paper and cite their sources.
The Absorb bioresorbable vascular scaffold (Absorb BVS, Abbott Vascular, Santa Clara, California) promises to address some of the residual shortcomings of existing metallic stents, such as late events induced by permanent caging of the coronary vessel. Scaffold restenosis (ScR) of BVS has been poorly described so far and treatment strategies for this event remain to be codified. We report on a case series of 14 lesions in 12 patients presenting with ScR and discuss their anatomical features and management strategies.
No takes yet. Share an insight, caveat, or question.
Longo et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: